Apellis Pharmaceuticals, Inc. (APLS) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

gentlemen. Thank you for standing by and welcome to the Appellate Pharmaceuticals fourth quarter and full year 2024 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to turn the call over to Meredith Kaya, Senior Vice President, Investor Relations and Strategic Finance. Please go ahead. Good morning, and thank you for joining us to discuss the Pellis' fourth quarter and full year 2024 financial results. With me on the call are co-founder and Chief Executive Officer, Dr. Cedric Francois, Executive Vice President of Commercial, David Apteson, Chief Medical Officer, Dr. Caroline Baumel, and Chief Financial Officer Tim Sullivan. Before we begin, let me point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail. Now, I'll turn the call over to Cedric. Thank you, Meredith, and thank you all for joining us this morning. As we close out another year, I would like to recognize the progress our team has made. We achieved important milestones in 2024, strengthening our business while navigating some headwinds along the way. CIFOV regenerated over 120% year-over-year U.S. net revenue growth. We presented positive Phase II...